Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

3. Notes

14. Impairment of non-financial assets

14. Impairment of non-financial assets

A review of the recoverable amounts of the Group’s assets did not lead the recognition of impairment charges in 2020 (2019: € 2 million, relating to the micro RNA targeting platform acquired from Beryllium LLC).

No impairment charges for Group property, plant and equipment were recognized in 2020 (2019: € 0 million).

No reasonably possible change in a key assumption on which management has based its determination of the assets recoverable amounts would cause the assets carrying amount to exceed its recoverable amount.